Phibro Animal Health Corporation (PAHC) to Distribute Quarterly Dividend of $0.12 on September 23rd

Phibro Animal Health Corporation (NASDAQ:PAHC) announced a quarterly dividend on Tuesday, July 28th. Investors of record on Wednesday, September 2nd will be paid a dividend of 0.12 per share on Wednesday, September 23rd. This represents a c) dividend on an annualized basis and a yield of 1.3%. The ex-dividend date of this dividend is Wednesday, September 2nd.

Phibro Animal Health has a payout ratio of 23.9% indicating that its dividend is sufficiently covered by earnings. Analysts expect Phibro Animal Health to earn $3.33 per share next year, which means the company should continue to be able to cover its $0.48 annual dividend with an expected future payout ratio of 14.4%.

Phibro Animal Health Stock Up 1.6%

Shares of PAHC opened at $36.95 on Thursday. The company has a quick ratio of 1.26, a current ratio of 3.17 and a debt-to-equity ratio of 1.97. The business has a fifty day moving average of $32.59 and a 200 day moving average of $43.22. The company has a market cap of $1.50 billion, a PE ratio of 15.86, a P/E/G ratio of 0.51 and a beta of 0.46. Phibro Animal Health has a 52-week low of $25.58 and a 52-week high of $60.08.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.04. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. The business had revenue of $383.54 million for the quarter, compared to analysts’ expectations of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. On average, sell-side analysts expect that Phibro Animal Health will post 3.08 EPS for the current year.

Insider Activity at Phibro Animal Health

In related news, CEO Jack Bendheim sold 7,040 shares of the firm’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $55.80, for a total value of $392,832.00. Following the transaction, the chief executive officer owned 67,720 shares of the company’s stock, valued at $3,778,776. This trade represents a 9.42% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 50.13% of the company’s stock.

Hedge Funds Weigh In On Phibro Animal Health

A number of hedge funds have recently added to or reduced their stakes in the stock. KBC Group NV bought a new stake in shares of Phibro Animal Health during the first quarter valued at approximately $29,000. 1620 Investment Advisors Inc. boosted its holdings in shares of Phibro Animal Health by 77.4% in the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after purchasing an additional 295 shares during the period. Farther Finance Advisors LLC grew its stake in Phibro Animal Health by 113.2% in the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after purchasing an additional 386 shares in the last quarter. Rothschild Investment LLC increased its holdings in Phibro Animal Health by 2,500.0% during the 4th quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock worth $39,000 after purchasing an additional 1,000 shares during the period. Finally, iSAM Funds UK Ltd purchased a new position in Phibro Animal Health during the 3rd quarter worth $61,000. 99.34% of the stock is currently owned by institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.